273.04

2.75% 7.32

Illumina Inc (ILMN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ILMN? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$265.72

Offen:

$265.91

24-Stunden-Volumen:

2.83M

Relative Volume:

1.10

Marktkapitalisierung:

$41.23B

Einnahmen:

$4.39B

Nettoeinkommen (Verlust:

$853.00M

KGV:

49.56

EPS:

5.5097

Netto-Cashflow:

$556.00M

1W Leistung:

+1.13%

1M Leistung:

+28.04%

6M Leistung:

+114.35%

1J Leistung:

+174.96%

1-Tages-Spanne:

$265.39

$274.97

1-Wochen-Bereich:

$262.89

$280.17

52-Wochen-Spanne:

$88.00

$280.17

Illumina Inc Stock (ILMN) Company Profile

Firmenname

Illumina Inc

Sektor

Healthcare (1064)

Branche

Diagnostics & Research (48)

Telefon

(858) 202-4500

Adresse

5200 ILLUMINA WAY, SAN DIEGO, CA

Mitarbeiter

8,650

Twitter

@illumina

Nächster Verdiensttermin

2026-10-29

Neueste SEC-Einreichungen

ILMN's Discussions on Twitter

Compare ILMN vs TMO, DHR, NTRA, A, IQV

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ILMN Illumina Inc	273.04	40.77B	4.39B	853.00M	556.00M	5.5097
TMO Thermo Fisher Scientific Inc	654.80	241.26B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	214.06	150.48B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	410.35	59.47B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	167.78	48.71B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	258.21	44.50B	16.63B	1.39B	2.12B	8.0674

Illumina Inc Stock (ILMN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-12	Herabstufung	Daiwa Securities	Outperform → Neutral
2025-07-11	Herabstufung	Scotiabank	Sector Outperform → Sector Perform
2025-03-04	Bestätigt	Citigroup	Neutral
2025-02-28	Herabstufung	HSBC Securities	Buy → Hold
2025-02-10	Herabstufung	Barclays	Equal Weight → Underweight
2025-02-07	Herabstufung	TD Cowen	Buy → Hold
2024-12-11	Herabstufung	Citigroup	Buy → Neutral
2024-11-12	Fortgesetzt	Morgan Stanley	Equal-Weight
2024-10-17	Hochstufung	HSBC Securities	Hold → Buy
2024-08-28	Hochstufung	Argus	Hold → Buy
2024-08-16	Hochstufung	Daiwa Securities	Neutral → Buy
2024-08-14	Hochstufung	Barclays	Underweight → Equal Weight
2024-08-14	Hochstufung	TD Cowen	Hold → Buy
2024-07-10	Hochstufung	Citigroup	Neutral → Buy
2024-06-03	Fortgesetzt	Jefferies	Hold
2024-01-16	Herabstufung	HSBC Securities	Buy → Hold
2024-01-04	Herabstufung	TD Cowen	Outperform → Market Perform
2023-12-18	Hochstufung	Scotiabank	Sector Perform → Sector Outperform
2023-12-15	Hochstufung	Bernstein	Underperform → Mkt Perform
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-14	Eingeleitet	Stephens	Overweight
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-12-12	Herabstufung	BofA Securities	Neutral → Underperform
2023-12-11	Hochstufung	Citigroup	Sell → Neutral
2023-11-10	Herabstufung	Canaccord Genuity	Buy → Hold
2023-09-28	Eingeleitet	Bernstein	Underperform
2023-07-05	Fortgesetzt	JP Morgan	Neutral
2023-01-25	Herabstufung	Argus	Buy → Hold
2023-01-05	Eingeleitet	Scotiabank	Sector Perform
2022-12-12	Herabstufung	Citigroup	Neutral → Sell
2022-12-07	Eingeleitet	RBC Capital Mkts	Outperform
2022-10-04	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2022-09-28	Hochstufung	Evercore ISI	In-line → Outperform
2022-08-25	Eingeleitet	Credit Suisse	Neutral
2022-07-13	Herabstufung	Barclays	Equal Weight → Underweight
2022-01-18	Hochstufung	Stifel	Hold → Buy
2022-01-11	Hochstufung	Barclays	Underweight → Equal Weight
2022-01-07	Hochstufung	BofA Securities	Underperform → Neutral
2022-01-06	Fortgesetzt	Morgan Stanley	Equal-Weight
2022-01-06	Fortgesetzt	Piper Sandler	Overweight
2021-10-15	Fortgesetzt	Cowen	Outperform
2021-08-19	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-06-01	Hochstufung	Evercore ISI	Underperform → In-line
2021-03-31	Herabstufung	Atlantic Equities	Overweight → Neutral
2021-03-31	Hochstufung	Canaccord Genuity	Hold → Buy
2021-03-03	Eingeleitet	Barclays	Underweight
2020-12-22	Hochstufung	Piper Sandler	Neutral → Overweight
2020-12-17	Hochstufung	BTIG Research	Neutral → Buy
2020-10-13	Herabstufung	Guggenheim	Buy → Neutral
2020-09-30	Eingeleitet	Atlantic Equities	Overweight
2020-09-29	Herabstufung	Wolfe Research	Outperform → Peer Perform
2020-09-22	Herabstufung	Stifel	Buy → Hold
2020-09-22	Herabstufung	UBS	Buy → Neutral
2020-09-21	Hochstufung	Guggenheim	Neutral → Buy
2020-09-21	Herabstufung	JP Morgan	Overweight → Neutral
2020-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2020-08-07	Herabstufung	Evercore ISI	In-line → Underperform
2020-08-07	Herabstufung	Piper Sandler	Overweight → Neutral
2020-07-07	Herabstufung	Guggenheim	Buy → Neutral
2020-04-24	Herabstufung	Citigroup	Buy → Neutral
2020-04-21	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-01-08	Eingeleitet	Wells Fargo	Underweight
2020-01-07	Eingeleitet	Citigroup	Buy
2020-01-02	Herabstufung	Evercore ISI	Outperform → In-line
2019-11-15	Eingeleitet	Stifel	Buy
2019-10-25	Eingeleitet	Guggenheim	Buy

Alle ansehen

Illumina Inc Aktie (ILMN) Neueste Nachrichten

Oct 01, 2026

Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.

Oct 01, 2026

Guggenheim Adjusts Price Target on Illumina to $305 From $226, Keeps Buy Rating - marketscreener.com

Oct 01, 2026

Sep 30, 2026

The Benchmark Matters: Evaluating TruPath Genome Beyond Individual Loci - Illumina

Sep 30, 2026

Illumina stock fell 1.42 percent to USD 270.00 on September 25, 2026 - AD HOC NEWS

Sep 28, 2026

Sep 26, 2026

Illumina Inc Hired Firms, 2022 - OpenSecrets

Sep 26, 2026

Sep 25, 2026

Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch

Sep 25, 2026

Illumina Stock Popped 7% to a 52-Week High. Here’s Where the Stock Goes From Here - Yahoo Finance

Sep 25, 2026

Illumina (ILMN) Tests Valuation As Russell Index Removal Forces A Fresh Look - Yahoo Finance

Sep 25, 2026

Illumina stock heads into the open after an 8.87 percent gain - AD HOC NEWS

Sep 25, 2026